

March 5, 2019



# BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March

## Company presentations at Cowen and Barclays Healthcare Conferences

NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 39th Annual Cowen Healthcare Conference being held March 11-13, 2019 in Boston, Massachusetts and the 2019 Barclays Global Healthcare Conference being held March 12-14, 2019 in Miami, Florida. BTI is a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.

Details of the presentations are below:

Event: 39th Annual Cowen Healthcare Conference

Date: March 11, 2019

Time: 4:50 PM ET

Event: 2019 Barclays Global Healthcare Conference

Date: March 12, 2019

Time: 9:30 AM ET

A live webcast of the presentations will be accessible through the Investors section of the Company's website at [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com). Following the conferences, the webcast will be archived on the BioXcel Therapeutics, Inc. website for 30 days.

In addition to his presentation, Dr. Mehta will be hosting 1-on-1 investor meetings at the conferences. Investors attending the conferences who are interested in meeting with BTI management should contact their Cowen and Barclays representatives.

### **About BioXcel Therapeutics, Inc.:**

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com).

### **Contact Information:**

BioXcel Therapeutics  
The Ruth Group  
Lee Roth/ Janhavi Mohite  
646-536-7012/ 7026  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)/ [jmohite@theruthgroup.com](mailto:jmohite@theruthgroup.com)

Source: BioXcel Therapeutics, Inc.